Renal Cell Carcinoma – Landscape & Forecast – Disease Landscape & Forecast

The renal cell carcinoma market is witnessing a substantial change, largely fueled by label expansions of immune checkpoint inhibitor therapies. Combination regimens, including Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical), Keytruda (Merck & Co.) plus Inlyta (Pfizer), and Bavencio (Pfizer / Merck KGaA) plus Inlyta, are revolutionizing the treatment of advanced disease. The recent approval and uptake of the Opdivo plus Cabometyx (Exelixis / Ipsen) combination will also drive fierce competition in this setting. Multiple immune checkpoint inhibitors are also anticipated to enter the early-stage setting over the forecast period. Additionally, the anticipated entry of other agents such as bempegaldesleukin (Nektar Therapeutics) and belzutifan (Merck & Co.) will further diversify treatment options and create a highly competitive and dynamic market.

Questions Answered

  • What is the size of the advanced or metastatic drug-treatable renal cell carcinoma population, and how will drug-treatment rates change over time?
  • What is the expected market impact of recent drug approvals and label expansions of novel combinations incorporating Opdivo, Cabometyx, and Keytruda for renal cell carcinoma?
  • Which are the most promising emerging therapies in the late-phase pipeline, and how will they shape the future of the renal cell carcinoma?
  • What are the drivers and constraints in the renal cell carcinoma market, and how will the market evolve over the forecast period?

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution Enhancement

Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Renal Cell Carcinoma - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q4 2021
        • November 2021
        • October 2021
      • Q3 2021
        • September 2021
        • August 2021
      • Q2 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • December 2020
    • Key Findings
      • Market Outlook
        • Key Findings
          • Market Share of Drug Classes for Renal Cell Carcinoma: 2020
          • Market Share of Drug Classes for Renal Cell Carcinoma: 2030
          • Drug-Treatable Population Share and Major-Market Sales Share in Renal Cell Carcinoma: 2020
          • Drug-Treatable Population Share and Major-Market Sales Share in Renal Cell Carcinoma: 2030
          • Population Positioning of Current Therapies in Renal Cell Carcinoma
          • Population Positioning of Emerging Therapies in Renal Cell Carcinoma
          • Renal Cell Carcinoma SWOT Analysis
        • Market Drivers and Constraints
          • What Factors Are Driving the Market for Renal Cell Carcinoma?
          • What Factors Are Constraining the Market for Renal Cell Carcinoma?
          • Major-Market Sales for Renal Cell Carcinoma by Drug-Treatable Population, 2020-2030
          • Major-Market Sales of Immune Oncology Therapies for Renal Cell Carcinoma, 2020-2030
          • Major-Market Sales of Angiogenesis Inhibitors for Renal Cell Carcinoma, 2020-2030
        • Segment-Specific Trends
          • Patient-Share Dynamics of Therapies for Early-Stage (Stage I-III) Renal Cell Carcinoma, United States, 2020-2030
          • Patient-Share Dynamics of Key Therapies in First-Line Advanced or Metastatic Renal Cell Carcinoma, United States, 2020-2030
          • Patient-Share Dynamics of Key Therapies in First-Line Advanced or Metastatic Renal Cell Carcinoma, Japan, 2020-2030
          • Patient-Share Dynamics of Key Therapies in Second-Line Advanced or Metastatic Renal Cell Carcinoma, United States, 2020-2030
          • Patient-Share Dynamics of Key Therapies in Second-Line Advanced or Metastatic Renal Cell Carcinoma, Japan, 2020-2030
          • Patient-Share Dynamics of Key Therapies in Third-Line Advanced or Metastatic Renal Cell Carcinoma, United States, 2020-2030
          • Patient-Share Dynamics of Key Therapies in Third-Line Advanced or Metastatic Renal Cell Carcinoma, Japan, 2020-2030
          • Patient-Share Dynamics of Key Therapies in Fourth-Line Advanced or Metastatic Renal Cell Carcinoma, United States, 2020-2030
          • Patient-Share Dynamics of Key Therapies in Fourth-Line Advanced or Metastatic Renal Cell Carcinoma, Japan, 2020-2030
      • Forecast
        • Market Forecast Assumptions
        • Market Forecast Dashboard
      • Etiology and Pathophysiology
        • Disease Overview
          • Progression of Renal Cell Carcinoma
          • Anatomy and Histology of Renal Cell Carcinoma
          • Prognostic Models for Renal Cell Carcinoma
          • International Metastatic Renal Cell Carcinoma Database Consortium Risk Assessment System for Stage IV Renal Cell Carcinoma
          • UCLA Integrated Staging System for Renal Cell Carcinoma
          • Classification of Renal Cell Carcinoma
          • Staging of Renal Cell Carcinoma
          • TNM Staging System for Renal Cell Carcinoma
          • Definitions of the TNM Staging System for Renal Cell Carcinoma
          • Key Pathways and Drug Targets for Renal Cell Carcinoma
      • Epidemiology
        • Key Findings
          • Key Updates
        • Epidemiology Populations
          • Disease Definition
          • Methods
          • Sources Used for Diagnosed Incidence of Renal Cell Carcinoma
          • Diagnosed Incident Cases of Renal Cell Carcinoma: 2020-2030
          • Disease Definition
          • Methods
          • Sources Used for Stage Distribution of Renal Cell Carcinoma
          • Diagnosed Incident Cases of Renal Cell Carcinoma by Stage Distribution: 2020-2030
          • Disease Definition
          • Methods
          • Sources Used for Recurrent Incidence of Renal Cell Carcinoma
          • Recurrent Incident Cases of Renal Cell Carcinoma: 2020-2030
          • Renal Cell Carcinoma Patient Flow
          • Drug-Treatable Cases of Renal Cell Carcinoma: 2020-2030
          • Drug-Treated Cases of Renal Cell Carcinoma: 2020-2030
      • Current Treatment
        • Key Findings
          • Treatment Goals
            • Key Endpoints Used in Clinical Trials for Renal Cell Carcinoma
          • Key Current Therapies
            • Overview
            • Mechanism of Action of Key Current Drug Classes Used for Renal Cell Carcinoma
            • Current Treatments Used for Renal Cell Carcinoma
            • Market Events Influencing the Use of Key Current Therapies in Renal Cell Carcinoma
            • Key Results From Select Clinical Trials Investigating Opdivo for the Treatment of Renal Cell Carcinoma
            • Ongoing Clinical Development of Opdivo
            • Key Ongoing Clinical Trials of Opdivo in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Opdivo
            • Key Results From Select Clinical Trials Investigating Opdivo and Yervoy Combination Therapy for the Treatment of Renal Cell Carcinoma
            • Ongoing Clinical Development of Opdivo and Yervoy Combination Therapy
            • Key Ongoing Clinical Trials of Opdivo and Yervoy Combination Therapy in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Opdivo and Yervoy Combination Therapy
            • Key Results From Select Clinical Trials Investigating Keytruda for the Treatment of Renal Cell Carcinoma
            • Ongoing Clinical Development of Keytruda
            • Key Ongoing Clinical Trials of Keytruda in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Keytruda
            • Key Results From Select Clinical Trials Investigating Bavencio for the Treatment of Renal Cell Carcinoma
            • Ongoing Clinical Development of Bavencio
            • Key Ongoing Clinical Trials of Bavencio in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Bavencio
            • Key Results From Select Clinical Trials Investigating Sutent for the Treatment of Renal Cell Carcinoma
            • Expert Insight: Sutent
            • Key Results From Select Clinical Trials Investigating Votrient for the Treatment of Renal Cell Carcinoma
            • Expert Insight: Votrient
            • Advantages and Disadvantages of Nexavar
            • Expert Insight: Nexavar
            • Key Results From Select Clinical Trials Investigating Inlyta for the Treatment of Renal Cell Carcinoma
            • Expert Insight: Inlyta
            • Ongoing Clinical Development of Avastin
            • Expert Insight: Avastin
            • Key Results From Select Clinical Trials Investigating Cabometyx for the Treatment of Renal Cell Carcinoma
            • Ongoing Clinical Development of Cabometyx
            • Key Ongoing Clinical Trials of Cabometyx in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Cabometyx
            • Key Results From Select Clinical Trials Investigating Lenvima / Kisplyx for the Treatment of Renal Cell Carcinoma
            • Ongoing Clinical Development of Lenvima / Kisplyx
            • Key Ongoing Clinical Trials of Lenvima / Kisplyx in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Lenvima / Kisplyx
            • Key Results From Select Clinical Trials Investigating Fotivda for the Treatment of Renal Cell Carcinoma
            • Ongoing Clinical Development of Fotivda
            • Key Ongoing Clinical Trials of Fotivda in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Fotivda
            • Advantages and Disadvantages of Torisel
            • Expert Insight: Torisel
            • Ongoing Clinical Development of Afinitor
            • Key Ongoing Clinical Trials of Afinitor in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Afinitor
            • Key Results From Select Clinical Trials Investigating Welireg for the Treatment of Renal Cell Carcinoma
            • Ongoing Clinical Development of Welireg
            • Key Ongoing Clinical Trials of Welireg in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Welireg
          • Medical Practice
            • Early-Stage Renal Cell Carcinoma: Stages I-III
            • First-Line Advanced or Metastatic Renal Cell Carcinoma: Stage IV
            • Second-Line Advanced or Metastatic Renal Cell Carcinoma
            • Third- and Fourth-Line Advanced or Metastatic Renal Cell Carcinoma
            • Patient Characteristics Influencing Drug Selection in Renal Cell Carcinoma
            • Treatment Decision Tree for Renal Cell Carcinoma: United States
            • Treatment Decision Tree for Renal Cell Carcinoma: EU5
            • Treatment Decision Tree for Renal Cell Carcinoma: Japan
        • Unmet Need Overview
          • Current and Future Attainment of Unmet Needs in Renal Cell Carcinoma
          • Top Unmet Needs in Renal Cell Carcinoma: Current and Future Attainment
          • Expert Insight: Unmet Need in Renal Cell Carcinoma
        • Emerging Therapies
          • Key Findings
            • Key Emerging Therapies
              • Key Therapies in Development for Renal Cell Carcinoma
              • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Renal Cell Carcinoma
              • Analysis of Clinical Development Program for Tecentriq
              • Key Ongoing Clinical Trials of Tecentriq in the Treatment of Renal Cell Carcinoma
              • Expert Insight: Tecentriq
              • Key Results From Select Clinical Trials Investigating Imfinzi for the Treatment of Renal Cell Carcinoma
              • Analysis of the Clinical Development Program for Imfinzi
              • Key Ongoing Clinical Trials of Imfinzi in the Treatment of Renal Cell Carcinoma
              • Expert Insight: Imfinzi
              • Expectations for Market Authorization and Sales Opportunity of Imfinzi in Renal Cell Carcinoma
              • Key Results From Select Clinical Trials Investigating Tremelimumab for the Treatment of Renal Cell Carcinoma
              • Analysis of Clinical Development Program for Tremelimumab
              • Key Ongoing Clinical Trials of Imfinzi in the Treatment of Renal Cell Carcinoma
              • Expert Insight: Tremelimumab
              • Expectations for Market Authorization and Sales Opportunity of Tremelimumab in Renal Cell Carcinoma
              • Key Results From Select Clinical Trials Investigating Orpathys for the Treatment of Renal Cell Carcinoma
              • Analysis of Clinical Development Program for Orpathys
              • Key Ongoing Clinical Trials of Orpathys in the Treatment of Renal Cell Carcinoma
              • Expert Insight: Orpathys
              • Expectations for Market Authorization and Sales Opportunity of Orpathys in Renal Cell Carcinoma
              • Key Results From Select Clinical Trials Investigating Dovitinib for the Treatment of Renal Cell Carcinoma
              • Analysis of Clinical Development Program for Dovitinib
              • Expert Insight: Dovitinib
              • Expectations for Market Authorization and Sales Opportunity of Dovitinib in Renal Cell Carcinoma
              • Key Results From Select Clinical Trials Investigating Bempegaldesleukin for the Treatment of Renal Cell Carcinoma
              • Analysis of the Clinical Development Program for Bempegaldesleukin
              • Key Ongoing Clinical Trials of Bempegaldesleukin in the Treatment of Renal Cell Carcinoma
              • Expert Insight: Bempegaldesleukin
              • Expectations for Market Authorization and Sales Opportunity of Bempegaldesleukin in Renal Cell Carcinoma
              • Key Results From Select Clinical Trials Investigating Abexinostat for the Treatment of Renal Cell Carcinoma
              • Analysis of Clinical Development Program for Abexinostat
              • Key Ongoing Clinical Trials of Abexinostat in the Treatment of Renal Cell Carcinoma
              • Expert Insight: Abexinostat
              • Expectations for Market Authorization and Sales Opportunity of Abexinostat in Renal Cell Carcinoma
            • Early-Phase Pipeline Analysis
            • Access and Reimbursement Overview
              • Region-Specific Reimbursement Practices
                • Key Market Considerations in Renal Cell Carcinoma: United States
                • General Reimbursement Environment: United States
                • Key Market Access Considerations in Renal Cell Carcinoma: EU5
                • General Reimbursement Environment: EU5
                • Key Market Access Considerations in Renal Cell Carcinoma: Japan
                • General Reimbursement Environment: Japan
            • Appendix
              • Renal Cell Carcinoma Bibliography